Gynecologic Oncology Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gynecologic Oncology Group sits in the top decile of US sponsors by registered trial count (#189 of 15,742 sponsors by registered trial count).
Gynecologic Oncology Group: 154 sponsored US clinical trials, 1 recruiting.
Gynecologic Oncology Group sponsors 154 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 115 completed. 27 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Cancer, with 6 trials.
Top-decile sponsor footprint
Gynecologic Oncology Group ranks in the top decile of sponsors by registered trial count (#189 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
115 of 151 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
154 total, page 2 of 4
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
NCT00305695
Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy
NCT00096187
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
NCT00081263
Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
NCT00112489
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
NCT00114218
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
NCT00087126
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
NCT00031629
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
NCT00104910
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00114166
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
NCT00068406
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
NCT00101192
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
NCT00087113
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00087087
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
NCT00085332
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00086892
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
NCT00070317
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
NCT00064025
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
NCT00084448
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
NCT00101127
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
NCT00068549
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00066456
Vaginal Changes and Sexual Function in Patients With Cervical Cancer
NCT00053261
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
NCT00049231
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
NCT00064077
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
NCT00060359
Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
NCT00058071
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
NCT00054067
Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva
NCT00028951
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00054119
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00045682
Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
NCT00017134
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00041093
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00039442
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
NCT00033644
Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT00030472
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00023699
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
NCT00017004
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00023894
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00023907
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00020696
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
NCT00016341
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
NCT00016926
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00006812
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva
NCT00006096
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00011986
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
NCT00006028
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT00006227
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
NCT00006482
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT00006224
Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
NCT00005031
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 86 |
| Phase 3 | 27 |
Therapeutic Areas
What is open in the Gynecologic Oncology Group pipeline
1 recruiting of 154 indexed (1% open); 115 completed (75%).
Phase mix: 27 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Cervical Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gynecologic Oncology Group: open-pipeline peers nationwide
Peers matched on 154 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Gynecologic Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 154 trials (± recruiting share)
- Sanofi Pasteur, a Sanofi Company · 153 trials · 2% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Galderma R&D · 158 trials · 4% recruiting
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- Shire · 0% recruiting · 245 trials
- Abbott Nutrition · 1% recruiting · 89 trials
Related
What to do with this Gynecologic Oncology Group page
154 registered trials is a research-attention snapshot, not an endorsement of Gynecologic Oncology Group or any single study.
- 1 of Gynecologic Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Cancer is the condition Gynecologic Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gynecologic Oncology Group pipeline card: 154 registered trials from official public datasets.Report a data error.